JP2021523241A5 - - Google Patents

Info

Publication number
JP2021523241A5
JP2021523241A5 JP2021514292A JP2021514292A JP2021523241A5 JP 2021523241 A5 JP2021523241 A5 JP 2021523241A5 JP 2021514292 A JP2021514292 A JP 2021514292A JP 2021514292 A JP2021514292 A JP 2021514292A JP 2021523241 A5 JP2021523241 A5 JP 2021523241A5
Authority
JP
Japan
Prior art keywords
hydrogen
alkyl
pharmaceutically acceptable
group
ring
Prior art date
Application number
JP2021514292A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523241A (ja
JP7343571B2 (ja
JPWO2019222157A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/032131 external-priority patent/WO2019222157A1/en
Publication of JP2021523241A publication Critical patent/JP2021523241A/ja
Publication of JP2021523241A5 publication Critical patent/JP2021523241A5/ja
Publication of JPWO2019222157A5 publication Critical patent/JPWO2019222157A5/ja
Priority to JP2023140718A priority Critical patent/JP2023164905A/ja
Application granted granted Critical
Publication of JP7343571B2 publication Critical patent/JP7343571B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514292A 2018-05-15 2019-05-14 マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 Active JP7343571B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023140718A JP2023164905A (ja) 2018-05-15 2023-08-31 マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671753P 2018-05-15 2018-05-15
US62/671,753 2018-05-15
PCT/US2019/032131 WO2019222157A1 (en) 2018-05-15 2019-05-14 Matrix metalloproteinase (mmp) inhibitors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023140718A Division JP2023164905A (ja) 2018-05-15 2023-08-31 マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法

Publications (4)

Publication Number Publication Date
JP2021523241A JP2021523241A (ja) 2021-09-02
JP2021523241A5 true JP2021523241A5 (https=) 2022-03-15
JPWO2019222157A5 JPWO2019222157A5 (https=) 2022-03-15
JP7343571B2 JP7343571B2 (ja) 2023-09-12

Family

ID=66690981

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2021514292A Active JP7343571B2 (ja) 2018-05-15 2019-05-14 マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法
JP2021514291A Active JP7344959B2 (ja) 2018-05-15 2019-05-14 マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法
JP2023140718A Pending JP2023164905A (ja) 2018-05-15 2023-08-31 マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法
JP2023142664A Active JP7656669B2 (ja) 2018-05-15 2023-09-04 マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021514291A Active JP7344959B2 (ja) 2018-05-15 2019-05-14 マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法
JP2023140718A Pending JP2023164905A (ja) 2018-05-15 2023-08-31 マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法
JP2023142664A Active JP7656669B2 (ja) 2018-05-15 2023-09-04 マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法

Country Status (20)

Country Link
US (6) US20190352288A1 (https=)
EP (4) EP4335499A3 (https=)
JP (4) JP7343571B2 (https=)
KR (3) KR102861502B1 (https=)
CN (3) CN112424186A (https=)
AU (3) AU2019269409B2 (https=)
BR (1) BR112020023269A2 (https=)
CA (2) CA3100320A1 (https=)
DK (2) DK3793995T3 (https=)
ES (2) ES2978192T3 (https=)
FI (2) FI3793992T3 (https=)
HU (2) HUE066619T2 (https=)
LT (1) LT3793995T (https=)
MY (1) MY199200A (https=)
PL (1) PL3793995T3 (https=)
PT (2) PT3793992T (https=)
SG (2) SG11202011316RA (https=)
SI (1) SI3793995T1 (https=)
TW (3) TWI827601B (https=)
WO (2) WO2019222157A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532102B2 (en) * 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
SI3793995T1 (sl) 2018-05-15 2024-05-31 Foresee Pharmaceuticals Usa, Inc. Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe
CA3158234A1 (en) * 2019-11-14 2021-05-20 Foresee Pharmaceuticals Co., Ltd. Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
EP4351566A4 (en) * 2021-06-08 2025-04-23 Foresee Pharmaceuticals USA, Inc. SAFE ADMINISTRATION OF MMP-12 INHIBITOR
TW202313011A (zh) * 2021-06-08 2023-04-01 逸達生物科技股份有限公司 Mmp抑制劑於治療急性呼吸窘迫綜合症之用途
EP4198033A1 (en) 2021-12-14 2023-06-21 Basf Se Heterocyclic compounds for the control of invertebrate pests
WO2023110473A1 (en) 2021-12-14 2023-06-22 Basf Se Heterocyclic compounds for the control of invertebrate pests

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2482618A1 (fr) 1980-05-16 1981-11-20 Inst Corps Gras Iterg Procede de conjugaison catalytique de corps gras polyinsatures, produits obtenus et application
US6352976B1 (en) 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
EP1150975A1 (en) 1998-12-31 2001-11-07 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
EP1288199A4 (en) 2000-04-28 2005-10-12 Shionogi & Co INHIBITORS OF MMP-12
JP2004527511A (ja) 2001-03-15 2004-09-09 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼ阻害剤
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US6890915B2 (en) 2001-05-25 2005-05-10 Bristol-Myers Squibb Pharma Company Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
EP1394159A1 (fr) 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
AU2003282920A1 (en) 2002-10-04 2004-05-04 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
US7132432B2 (en) * 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
JP5042833B2 (ja) 2004-08-19 2012-10-03 クエスト ファーマシューティカル サーヴィシーズ マクロファージエラスターゼの阻害剤としての5−[3−(4−ベンジルオキシフェニルチオ)−フラ−2−イル]−イミダゾリジン−2,4−ジオン及び類似体
EP2797002A4 (en) 2011-12-21 2015-05-20 Panasonic Corp DATA PROCESSING DEVICE, DATA TRANSMISSION DEVICE, DATA PROCESSING SYSTEM, DATA PROCESSING METHOD AND DATA TRANSMISSION METHOD
SI3793995T1 (sl) * 2018-05-15 2024-05-31 Foresee Pharmaceuticals Usa, Inc. Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe

Similar Documents

Publication Publication Date Title
JP2021523241A5 (https=)
FI3793995T3 (fi) Matriksin metalloproteinaasin (mmp) estäjiä ja niiden käyttömenetelmiä
JP2009544602A5 (https=)
CN110582489A (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
JP2019518766A5 (https=)
JP2019504898A5 (https=)
ME03804B (me) Karbamoiloksimetil triazol cikloheksilne kiseline kao antagonisti lpa
MY152955A (en) Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
JP2020521741A5 (https=)
CN110573501A (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
RU2011110908A (ru) Тиенопиримидины для фармацевтических композиций
JP2021523240A5 (https=)
ME02675B (me) Novi derivati cikloheksilamina sa aktivnostima beta2 adrenergijskog agonista i m3 muscarinskog antagonista
CA2412968A1 (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
JP2013523802A5 (https=)
JP2007524696A5 (https=)
JP2008546791A5 (https=)
JP2016535042A5 (https=)
JP2017132814A5 (https=)
JP2007534702A5 (https=)
JP2011507929A5 (https=)
JP2006517976A5 (https=)
JP2015511232A5 (https=)
HRP20200016T1 (hr) Amidno supstituirani tiazoli kao modulatori rorgamat
JP2019501927A5 (https=)